Bristol Myers radiopharma drug slows rare tumor growth
Bristol Myers Squibb reported its experimental radiopharmaceutical therapy RYZ101 significantly delayed disease progression in patients with rare advanced tumors. The late-stage trial results validate the drugmaker platform following its acquisition of RayzeBio.
Xurve View
Insights:
Xurve View
Bristol-Myers Squibb Co reported that its RYZ101 radiopharmaceutical therapy delayed disease progression in patients with rare gastrointestinal and pancreatic tumors during a late-stage trial. Shares of the drugmaker rose 2% following the announcement on Monday afternoon. The therapy targets advanced tumors using the radioactive isotope actinium-225 after earlier treatments fail.
